STOCK TITAN

Farb Files Schedule 13D: 9.8% Position and Board Nominations at ATLEW

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
SCHEDULE 13D

Rhea-AI Filing Summary

Daniel S. Farb filed a Schedule 13D disclosing a 9.8% direct stake in Artelo Biosciences, Inc. 153,000 shares purchased with personal funds for approximately $850,019. Farb also acquired warrants under a June 2025 Securities Purchase Agreement: 11,299 $10 warrants and 22,598 $5.82 warrants. He exercised all $5.82 warrants on July 23, 2025, and received 22,595 shares; the issuer declined delivery of 3 shares and intends to pay $17.46 for those undelivered shares. Farb delivered a director nomination letter naming himself and Scott D. Pomfret and entered a Joint Filing and Solicitation Agreement with Pomfret; Pomfret granted Farb a power of attorney to assist with the proxy solicitation. The registered resale of the SPA securities was filed on Form S-1.

Positive

  • Significant equity position: Directly owns 153,000 shares (~9.8%) of ATLEW
  • Activated governance: Nominated two director candidates and formed a solicitation group with a Joint Filing and Solicitation Agreement
  • Committed capital: Shares were purchased with personal funds totaling approximately $850,019
  • Resale registration: Securities purchased under the June 2025 SPA were registered on Form S-1

Negative

  • Beneficial ownership cap: Warrants are subject to a 4.99% ownership limitation, preventing current exercise into additional shares beyond that cap
  • Delivery discrepancy: Exercise of $5.82 warrants resulted in 3 undelivered shares; issuer plans to pay $17.46 in lieu of delivering those shares

Insights

TL;DR: A near-10% stake plus board nominations and a formal solicitation group are material and could trigger shareholder re-evaluation.

The Reporting Person's 9.8% direct ownership is sizable relative to the disclosed 1,555,493 shares outstanding and is coupled with active governance steps: director nominations, a Joint Filing and Solicitation Agreement, and a power of attorney to support proxy activities. The use of personal funds and additional economic exposure via warrants

TL;DR: Formation of a solicitation group and board nominations signal an organized shareholder engagement effort that is governance-impactful.

The Reporting Person has taken formal governance actions: nominating two directors, entering a Joint Filing and Solicitation Agreement, and obtaining a power of attorney from his nominee. These documented arrangements establish a group for proxy solicitation and allocate expense and voting coordination, which materially raises the probability of a contested election or negotiated board changes. The nominee credentials provided are relevant to evaluating the group's credibility with other shareholders.






If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§ 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box.

The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).






SCHEDULE 13D






SCHEDULE 13D


Farb Daniel Stuart
Signature:/s/ Daniel S. Farb
Name/Title:Daniel S. Farb
Date:09/19/2025

FAQ

How many shares of ATLEW does Daniel S. Farb own?

The filing states Mr. Farb directly owns 153,000 shares, representing approximately 9.8% of outstanding shares based on 1,555,493 shares.

What warrants related to ATLEW does the filing disclose?

Mr. Farb owns 11,299 $10 warrants and 22,598 $5.82 warrants, with the $5.82 warrants exercised on July 23, 2025.

Did Mr. Farb nominate directors at Artelo Biosciences (ATLEW)?

Yes. On September 19, 2025, Mr. Farb delivered a letter nominating Daniel S. Farb and Scott D. Pomfret for election to the Board at the 2025 annual meeting.

What agreements did Mr. Farb enter regarding proxy solicitation?

Mr. Farb and Mr. Pomfret entered a Joint Filing and Solicitation Agreement dated September 18, 2025, and Mr. Pomfret granted Mr. Farb a power of attorney to execute solicitation filings.

How much did Mr. Farb pay for his 153,000 shares?

The aggregate purchase price for the 153,000 shares was approximately $850,019, excluding brokerage commissions.
Artelo Bioscienc

OTC:ATLEW

ATLEW Rankings

ATLEW Latest SEC Filings

ATLEW Stock Data